Insider Cluster (2 insiders) ·Filed Feb 25, 2026

VRTX

VERTEX PHARMACEUTICALS INC / MA
NEUTRAL
Impact 4/10
Horizondays Processed6mo ago
Insider cluster: 10 insiders, $5.1M total
Actionable Insight • Neutral

Monitor for additional insider sales in the next 30 days; while this cluster is within normal range for a company of this size, repeated selling by C-suite executives could signal waning confidence. Compare to historical patterns and upcoming earnings timing.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
VRTX ▼ -10.87% at T+60d
NEUTRAL call ✗ call lost -10.87% · α vs SPY -17.82% · entry $482.92 → $430.44
Entry anchored
Feb 24, 03:59 PM ET
via exchange tick
T+1d
-0.58%
call -0.58% · α -0.03%
$480.12
settled 7mo ago
T+5d
-1.32%
call -1.32% · α -0.22%
$476.54
settled 7mo ago
T+20d
-5.79%
call -5.79% · α -0.55%
$454.96
settled 6mo ago
T+60d
-10.87%
call -10.87% · α -17.82%
$430.44
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

Two Vertex Pharmaceuticals EVPs — the Chief Commercial Officer and Chief Legal Officer — sold shares in open-market transactions totaling approximately $1.6 million over the past week. These were opportunistic sales of existing holdings, not tied to a specific corporate event.

Key Financial Metrics

Direction
selling
Total Value
$1.6M
Insiders
2

Key Facts

  • EVP and Chief Commercial Officer Duncan McKechnie sold 2,437 shares for $1,158,306.10 at $475.30 per share on March 4, 2026.
  • EVP and Chief Legal Officer Joy Liu sold 892 shares for $442,396.32 at $495.96 per share on March 2, 2026.
  • Total value of the insider trading cluster: $1,600,702.42 in open-market sales.
  • Both transactions were reported on Form 4 as open-market sales (code 'S'), indicating deliberate dispositions.
  • Sales represent approximately 0.0014% of Vertex's $117.1B market cap — well below the 0.1% threshold for materiality.

Financial Impact

$1.6 million in total insider sales, or 0.0014% of market capitalization

insider ownershipmarket sentiment

Risk Factors

  • Perception risk if selling continues ahead of earnings or a product decision.
  • Concentration risk in executive ownership if such sales become a trend.

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CONTEXT: Insider Cluster Data (2 trades, 7d window)cluster-VRTX-1772831202282
11 reports for VRTX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for VRTX — sortable, filterable
TypeNow
Jul 7, 2026
12w ago
8-K
BULLISH ★ 7/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 7, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$522.25 $522.81▲ +0.11%▼ −1.89%$506.74 (−2.97%)
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$529.59 $526.73▼ −0.54%▼ −2.26%$506.74 (−4.31%)
Jun 3, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$441.47 $541.69▲ +22.70%▲ +21.08%$506.74 (+14.79%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$430.05 $505.75▲ +17.60%▲ +12.87%$506.74 (+17.83%)
Mar 11, 2026
29w ago
Insider Cluster
NEUTRAL ★ 3/10
$491.96 $428.34▼ −12.93%▼ −24.45%$506.74 (+3.01%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
BEARISH ★ 6/10
$482.92 $430.44▲ +10.87%▲ +17.82%$506.74 (−4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 3/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Feb 25, 2026
31w ago
Insider Cluster
NEUTRAL ★ 4/10
$482.92 $430.44▼ −10.87%▼ −17.82%$506.74 (+4.93%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 1h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Mar 6, 2026